Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy
Genetically modified bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and i...
Saved in:
Published in | Frontiers in immunology Vol. 8; p. 1961 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
17.01.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Genetically modified
bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and immunogenicity. Also, containment strategies have been developed to promote further application as clinical protein-based therapeutics. Here, we review technological advancements made to enhanced the potential of
as live biofactories and discuss some examples of tolerogenic immunotherapies mediated by mucosal drug delivery
. Additionally, we highlight their use to induce mucosal tolerance by targeted autoantigen delivery to the intestine as an approach to reverse autoimmune type 1 diabetes. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Specialty section: This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology Reviewed by: Femke Broere, Utrecht University, Netherlands; Joan Stein-Streilein, Schepens Eye Research Institute, United States Edited by: Luis Graça, Universidade de Lisboa, Portugal |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2017.01961 |